Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. more
Time Frame | BGNE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.5% | -3.39% | 0.2% |
1-Month Return | -4.6% | -1.92% | 2.72% |
3-Month Return | -9.34% | -10.54% | 7.31% |
6-Month Return | 12.35% | -4.47% | 10.44% |
1-Year Return | -1.86% | 4.06% | 27.53% |
3-Year Return | -34.58% | 0.94% | 30.88% |
5-Year Return | 9.95% | 36.67% | 89.21% |
10-Year Return | 532.27% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 428.21M | 308.87M | 1.18B | 1.42B | 2.46B | [{"date":"2019-12-31","value":17.42,"profit":true},{"date":"2020-12-31","value":12.56,"profit":true},{"date":"2021-12-31","value":47.84,"profit":true},{"date":"2022-12-31","value":57.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 998.53M | 1.37B | 1.62B | 1.93B | 379.92M | [{"date":"2019-12-31","value":51.82,"profit":true},{"date":"2020-12-31","value":70.86,"profit":true},{"date":"2021-12-31","value":84.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":19.72,"profit":true}] |
Gross Profit | (570.32M) | (1.06B) | (447.86M) | (511.06M) | 2.08B | [{"date":"2019-12-31","value":-27.43,"profit":false},{"date":"2020-12-31","value":-50.83,"profit":false},{"date":"2021-12-31","value":-21.54,"profit":false},{"date":"2022-12-31","value":-24.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (133.19%) | (342.10%) | (38.07%) | (36.09%) | 84.55% | [{"date":"2019-12-31","value":-157.53,"profit":false},{"date":"2020-12-31","value":-404.62,"profit":false},{"date":"2021-12-31","value":-45.03,"profit":false},{"date":"2022-12-31","value":-42.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 389.57M | 601.02M | 990.87M | 1.28B | 3.29B | [{"date":"2019-12-31","value":11.85,"profit":true},{"date":"2020-12-31","value":18.29,"profit":true},{"date":"2021-12-31","value":30.15,"profit":true},{"date":"2022-12-31","value":38.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (959.89M) | (1.66B) | (1.44B) | (1.79B) | (1.21B) | [{"date":"2019-12-31","value":-95989100000,"profit":false},{"date":"2020-12-31","value":-165768200000,"profit":false},{"date":"2021-12-31","value":-143873500000,"profit":false},{"date":"2022-12-31","value":-178966500000,"profit":false},{"date":"2023-12-31","value":-120773600000,"profit":false}] |
Total Non-Operating Income/Expense | 25.44M | 41.49M | (15.61M) | (118.89M) | 457.85M | [{"date":"2019-12-31","value":5.56,"profit":true},{"date":"2020-12-31","value":9.06,"profit":true},{"date":"2021-12-31","value":-3.41,"profit":false},{"date":"2022-12-31","value":-25.97,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (943.59M) | (1.62B) | (1.44B) | (1.96B) | (825.84M) | [{"date":"2019-12-31","value":-94358600000,"profit":false},{"date":"2020-12-31","value":-161819400000,"profit":false},{"date":"2021-12-31","value":-143858800000,"profit":false},{"date":"2022-12-31","value":-196103700000,"profit":false},{"date":"2023-12-31","value":-82583600000,"profit":false}] |
Income Taxes | 6.99M | (17.67M) | (25.23M) | 42.78M | 55.87M | [{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":-31.63,"profit":false},{"date":"2021-12-31","value":-45.16,"profit":false},{"date":"2022-12-31","value":76.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (950.58M) | (1.60B) | (1.41B) | (2.00B) | (881.71M) | [{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false}] |
Income From Continuous Operations | (950.58M) | (1.60B) | (1.41B) | (2.00B) | (959.49M) | [{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-95949000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (950.58M) | (1.60B) | (1.41B) | (2.00B) | (881.71M) | [{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false}] |
EPS (Diluted) | (15.74) | (19.02) | (15.16) | (19.51) | (11.71) | [{"date":"2019-12-31","value":-1574,"profit":false},{"date":"2020-12-31","value":-1902,"profit":false},{"date":"2021-12-31","value":-1516,"profit":false},{"date":"2022-12-31","value":-1951,"profit":false},{"date":"2023-12-31","value":-1171,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BGNE | |
---|---|
Cash Ratio | 1.33 |
Current Ratio | 1.93 |
Quick Ratio | 1.72 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BGNE | |
---|---|
ROA (LTM) | -9.58% |
ROE (LTM) | -23.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BGNE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.41 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.59 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BGNE | |
---|---|
Trailing PE | NM |
Forward PE | 384.62 |
P/S (TTM) | 0.85 |
P/B | 5.55 |
Price/FCF | 365 |
EV/R | 5.54 |
EV/Ebitda | NM |
PEG | NM |
BeiGene Ltd (BGNE) share price today is $175.113
Yes, Indians can buy shares of BeiGene Ltd (BGNE) on Vested. To buy BeiGene Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BGNE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BeiGene Ltd (BGNE) via the Vested app. You can start investing in BeiGene Ltd (BGNE) with a minimum investment of $1.
You can invest in shares of BeiGene Ltd (BGNE) via Vested in three simple steps:
The 52-week high price of BeiGene Ltd (BGNE) is $248.16. The 52-week low price of BeiGene Ltd (BGNE) is $126.97.
The price-to-earnings (P/E) ratio of BeiGene Ltd (BGNE) is
The price-to-book (P/B) ratio of BeiGene Ltd (BGNE) is 5.55
The dividend yield of BeiGene Ltd (BGNE) is 0.00%
The market capitalization of BeiGene Ltd (BGNE) is $19.97B
The stock symbol (or ticker) of BeiGene Ltd is BGNE